Thank you Angela Gabriel and your contributors for these insights on the value of fractional leadership in life sciences. In addition to cost savings, I thought I would highlight some other benefits of this evolving model.
Indeed, we started BiotechExec to address budget constraints in emerging life science companies. We have since expanded the model by incorporating trial C-suite roles that may later convert to full-time positions, and to consulting projects for companies and their investors led by these operating execs. This allows our clients to not only cut costs through the efficiency of these experienced professionals, but also minimize the risk of committing to full-time employment before both the company and executive have had time to assess their fit with one another. Plus, our nationwide executive presence removes the geographic limitations often faced by companies outside major life science hubs and brings the right domain expertise without compromise.
Consulting and fractional work isn’t for everyone—we exclusively accept CEOs and other CXOs into our Ignite Network with the strongest track records of success, referred only by trusted peers, and invest significant effort into onboarding them to ensure they are ideally suited for these roles.
We believe this "on demand" executive model is here to stay through both tough and strong investment climates.
For reasons including downsizing, avoiding retirement and a tight labor market, senior-level biopharma professionals are increasingly turning to fractional roles, according to two recruitment experts, Spiro Michas and Eric Charsky. In this article, one fractional leader, Philippe Prochasson, Ph.D. shares his thoughts.
#leadership #biopharma #biospace
https://hubs.li/Q02MV2mg0
Difficult Market Turns More Biopharma Leaders to Fractional Roles, Say Experts
The Black Weed Show connects Cannabis Business to Black people ???
7 个月#expungementandequity? #inclusionandinvestment? #cannabisismedicine #blackbusiness? #africanbusiness? #votingrights #theBWS